ATE254599T1 - Divalente sulfonyl-aryl-oder heteroaryl hydroxamsäureverbindungen - Google Patents

Divalente sulfonyl-aryl-oder heteroaryl hydroxamsäureverbindungen

Info

Publication number
ATE254599T1
ATE254599T1 AT98911481T AT98911481T ATE254599T1 AT E254599 T1 ATE254599 T1 AT E254599T1 AT 98911481 T AT98911481 T AT 98911481T AT 98911481 T AT98911481 T AT 98911481T AT E254599 T1 ATE254599 T1 AT E254599T1
Authority
AT
Austria
Prior art keywords
hydroxamic acid
aryl
acid compounds
sulfonyl
heteroaryl hydroxamic
Prior art date
Application number
AT98911481T
Other languages
English (en)
Inventor
Joseph J Mcdonald
Thomas E Barta
Daniel P Becker
Louis J Bedell
Shashidhar N Rao
John N Freskos
Brent V Mischke
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Application granted granted Critical
Publication of ATE254599T1 publication Critical patent/ATE254599T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98911481T 1997-03-04 1998-03-04 Divalente sulfonyl-aryl-oder heteroaryl hydroxamsäureverbindungen ATE254599T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3518297P 1997-03-04 1997-03-04
PCT/US1998/004300 WO1998038859A1 (en) 1997-03-04 1998-03-04 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds

Publications (1)

Publication Number Publication Date
ATE254599T1 true ATE254599T1 (de) 2003-12-15

Family

ID=21881145

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98911481T ATE254599T1 (de) 1997-03-04 1998-03-04 Divalente sulfonyl-aryl-oder heteroaryl hydroxamsäureverbindungen

Country Status (20)

Country Link
US (3) US6380258B2 (de)
EP (4) EP0984959B1 (de)
JP (4) JP2002513407A (de)
KR (3) KR20000075946A (de)
CN (3) CN1253474A (de)
AT (1) ATE254599T1 (de)
AU (2) AU750303B2 (de)
BR (2) BR9808214A (de)
CA (4) CA2283272A1 (de)
DE (1) DE69819878T2 (de)
DK (1) DK0973392T3 (de)
EA (1) EA199900792A1 (de)
ES (2) ES2209122T3 (de)
HK (1) HK1027806A1 (de)
IL (3) IL131494A (de)
NO (1) NO315647B1 (de)
NZ (1) NZ337326A (de)
PL (1) PL335732A1 (de)
PT (1) PT973392E (de)
WO (1) WO1998038859A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
US6696449B2 (en) * 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
IL131494A (en) 1997-03-04 2005-06-19 Monsanto Co N-hydroxy 4-sulfonyl butanamide compounds and their use to prepare medicaments for treating conditions associated with matrix metalloproteinase activity
AU763113B2 (en) * 1997-11-21 2003-07-10 Pharmacia & Upjohn Company Alpha-hydroxy, -amino, and halo derivatives of beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors
WO2000037433A1 (en) * 1998-12-18 2000-06-29 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
AU3312100A (en) 1999-03-22 2000-10-09 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
KR20020009610A (ko) * 1999-05-12 2002-02-01 윌리암스 로저 에이 매트릭스 메탈로프로테아제 억제제로서의 히드록삼산 유도체
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
DK1335898T3 (da) 2000-09-29 2006-04-03 Topotarget Uk Ltd Carbaminsyreforbindelser omfattende en amidbinding som HDAC-inhibitorer
JP4975941B2 (ja) * 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
YU103003A (sh) 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
ATE399012T1 (de) * 2002-04-03 2008-07-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
WO2003091247A2 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
GB0226855D0 (en) * 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
ES2537514T3 (es) 2003-04-04 2015-06-09 Incyte Corporation Composiciones, métodos y kits relacionados con la escisión de HER-2
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
ES2338243T3 (es) * 2004-03-22 2010-05-05 Southern Research Institute Inhibidores no peptidicos de metaloproteinasas matrices.
US20050250789A1 (en) * 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
US7348437B2 (en) * 2004-06-01 2008-03-25 The Scripps Research Institute Proteomic analysis
US20050277897A1 (en) * 2004-06-14 2005-12-15 Ghannoum Ziad R Handpiece tip
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
PL2364975T3 (pl) * 2008-10-27 2013-12-31 Mitsubishi Tanabe Pharma Corp Nowa pochodna amidu i jej zastosowanie jako lek
AU2010303270A1 (en) 2009-10-09 2012-05-03 Zafgen Corporation Sulphone compounds for use in the treatment of obesity
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
MX343688B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
CN104892457B (zh) * 2011-07-25 2017-07-28 中国医学科学院医药生物技术研究所 一种异羟肟酸类衍生物、其药物组合物、制备方法及用途
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
JP6035347B2 (ja) 2012-01-18 2016-11-30 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその作製および使用方法
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
MX2015005732A (es) 2012-11-05 2015-12-16 Zafgen Inc Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
CN104769090B (zh) * 2012-11-09 2018-01-02 荷兰联合利华有限公司 用于处理基底的组合物和方法
TW201625620A (zh) 2014-05-14 2016-07-16 美國科羅拉多州立大學 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
US10772876B2 (en) * 2016-03-17 2020-09-15 Xeniopro GmbH Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch
WO2020006384A1 (en) * 2018-06-29 2020-01-02 Loyola University Of Chicago Carborane hydroxamic acid matrix metalloproteinase inhibitors and agents for boron neutron capture therapy
CN111217722B (zh) * 2020-03-06 2024-01-02 华东理工大学 偶氮芳基脲类衍生物及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148801A (en) 1978-07-03 1979-04-10 American Home Products Corporation 3-[(Chlorophenylsulfonyl)methyl]-1,2,4-oxadiazole-5-carboxylic acid derivatives
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
US5103014A (en) 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
GB2212153B (en) 1987-11-16 1992-01-15 Squibb & Sons Inc Phenyl hydroxamic acids
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
US5527945A (en) * 1989-02-10 1996-06-18 Basf Aktiengesellschaft Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom
ES2110433T3 (es) * 1990-12-17 1998-02-16 Sankyo Co Derivados de pirazoles de actividad herbicida, su preparacion y su utilizacion.
DE69309047T2 (de) * 1992-04-07 1997-09-11 British Biotech Pharm Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
US5376664A (en) 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5646167A (en) 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9307956D0 (en) 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
GB9323165D0 (en) 1993-11-10 1994-01-05 Chiros Ltd Compounds
AU2394795A (en) 1994-04-28 1995-11-29 Du Pont Merck Pharmaceutical Company, The Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
DK0784629T3 (da) 1994-10-05 1999-10-25 Darwin Discovery Ltd Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteaser
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
EP1095936B1 (de) 1995-12-08 2004-11-24 Agouron Pharmaceuticals, Inc. Zwischenprodukte zur Herstellung von Metallproteinasehemmern
DK0780386T3 (da) * 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
DK0871439T3 (da) * 1996-01-02 2004-08-02 Aventis Pharma Inc Substituerede (aryl, heteroaryl, arylmethyl eller heteroarylmethyl) hydroxamsyreforbindelser
WO1997049679A1 (fr) 1996-06-27 1997-12-31 Ono Pharmaceutical Co., Ltd. Derives d'aryle (sulfure, oxyde sulfonique et sulfone) et medicaments les contenant en tant que principe actif
CA2263154A1 (en) * 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
ID21897A (id) * 1996-09-27 1999-08-05 Upjohn Co Asam b-sulfonil hidroksamat sebagai bahan penghambat matriks metaloproteinase
ATE205306T1 (de) * 1997-01-13 2001-09-15 Fuji Photo Film Co Ltd Wärmeentwickelbares, photoempfindliches farbmaterial
WO1998034915A1 (en) * 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
DE69823019T2 (de) * 1997-02-27 2005-03-31 Wyeth Holdings Corp. N-hydroxy-2-(alkyl, aryl oder heteroaryl sulfanyl, sulfinyl oder sulfonyl)-3-substituierte alkyl-, aryl- oder heteroarylamide als matrixmetalloproteinaseinhibitoren
IL131494A (en) 1997-03-04 2005-06-19 Monsanto Co N-hydroxy 4-sulfonyl butanamide compounds and their use to prepare medicaments for treating conditions associated with matrix metalloproteinase activity
US20010014688A1 (en) * 1997-11-14 2001-08-16 Thomas E. Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor

Also Published As

Publication number Publication date
NO315647B1 (no) 2003-10-06
EP0973392A4 (de) 2001-05-02
EA199900792A1 (ru) 2000-04-24
AU6542498A (en) 1998-09-22
AU6447898A (en) 1998-09-22
US20020103239A1 (en) 2002-08-01
IL131494A0 (en) 2001-01-28
AU750130B2 (en) 2002-07-11
IL131494A (en) 2005-06-19
CA2283145A1 (en) 1998-09-11
EP0983258A1 (de) 2000-03-08
ES2209122T3 (es) 2004-06-16
EP0973392A1 (de) 2000-01-26
HK1027806A1 (en) 2001-01-23
IL131493A (en) 2004-05-12
DE69819878D1 (de) 2003-12-24
CN1105114C (zh) 2003-04-09
DE69819878T2 (de) 2004-04-22
PT973392E (pt) 2004-04-30
BR9808214A (pt) 2000-05-16
EP0973392B1 (de) 2003-11-19
AU6686598A (en) 1998-09-22
CA2283272A1 (en) 1998-09-11
AU750303B2 (en) 2002-07-18
EP0984959A1 (de) 2000-03-15
JP2001518081A (ja) 2001-10-09
CN1253474A (zh) 2000-05-17
US6380258B2 (en) 2002-04-30
DK0973392T3 (da) 2004-03-29
US20040097487A1 (en) 2004-05-20
JP2002515900A (ja) 2002-05-28
PL335732A1 (en) 2000-05-08
CA2282318A1 (en) 1998-09-11
NO994252D0 (no) 1999-09-02
JP2002513407A (ja) 2002-05-08
BR9808166A (pt) 2000-05-16
IL131493A0 (en) 2001-01-28
KR20000075954A (ko) 2000-12-26
EP0983257A1 (de) 2000-03-08
CA2283275A1 (en) 1998-09-11
WO1998038859A1 (en) 1998-09-11
CN1253559A (zh) 2000-05-17
EP0984959B1 (de) 2003-09-24
EP0983257A4 (de) 2001-05-02
AU737329B2 (en) 2001-08-16
US6656954B2 (en) 2003-12-02
CN1254337A (zh) 2000-05-24
NO994252L (no) 1999-09-02
KR20000075955A (ko) 2000-12-26
EP0983258A4 (de) 2001-01-17
EP0984959A4 (de) 2001-05-02
JP2002515901A (ja) 2002-05-28
NZ337326A (en) 2001-05-25
ES2206903T3 (es) 2004-05-16
US20010020021A1 (en) 2001-09-06
IL131495A0 (en) 2001-01-28
KR20000075946A (ko) 2000-12-26

Similar Documents

Publication Publication Date Title
ATE254599T1 (de) Divalente sulfonyl-aryl-oder heteroaryl hydroxamsäureverbindungen
DK0977745T3 (da) Thioarylsulfonamidhydroxamsyreforbindelser
WO2001085680A3 (en) Sulfonyl aryl or heteroaryl hydroxamic acid compounds
AP2001002240A0 (en) Sufamato hydroxamic acid metalloprotease inhibitor.
NZ515197A (en) Hydroxamic acid derivatives useful as matrix metalloprotease inhibitors
ATE231837T1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
DE69737605D1 (de) Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten
MY120235A (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
NZ337298A (en) N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
DE60144064D1 (de) Sulfone, die die aktivität von gamma-secretase modulieren
NZ331327A (en) Serine protease inhibitors having an acylguanidine side chain
ATE266634T1 (de) Cyclobutyl-aryloxysulfonylamin- hydroxamsäurederivate
WO2003007954A3 (en) Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
MXPA04004803A (es) Acidos hidroxamicos de sulfonas aromaticas y su uso como inhibidores de la proteasa.
YU85403A (sh) Aromatični sulfonski hidroksamati i njihova upotreba kao proteaznih inhibitora
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
MY141460A (en) Aromatic sulfone hydroxamic acid metalloprotease inhibitor
TH66678A (th) สารยับยั้งเมทัลโลซีนของกรดซัลฟามาโตไฮดรอกซามิค

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0973392

Country of ref document: EP

REN Ceased due to non-payment of the annual fee